|
US4036945A
(en)
|
1976-05-03 |
1977-07-19 |
The Massachusetts General Hospital |
Composition and method for determining the size and location of myocardial infarcts
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
|
US4331647A
(en)
|
1980-03-03 |
1982-05-25 |
Goldenberg Milton David |
Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4545985A
(en)
*
|
1984-01-26 |
1985-10-08 |
The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services |
Pseudomonas exotoxin conjugate immunotoxins
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US5079163A
(en)
|
1985-03-29 |
1992-01-07 |
Cetus Corporation |
Recombinant ricin toxin fragments
|
|
US4689401A
(en)
|
1986-03-06 |
1987-08-25 |
Cetus Corporation |
Method of recovering microbially produced recombinant ricin toxin a chain
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4892827A
(en)
|
1986-09-24 |
1990-01-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
EP0531434B1
(en)
|
1990-05-11 |
1999-07-14 |
THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE |
Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
|
|
US5608039A
(en)
|
1990-10-12 |
1997-03-04 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Single chain B3 antibody fusion proteins and their uses
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
EP0630234B1
(en)
|
1992-03-12 |
1997-06-11 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release acth containing microspheres
|
|
WO1993019180A1
(en)
*
|
1992-03-17 |
1993-09-30 |
Ciba-Geigy Ag |
Genetically engineered antibodies
|
|
AU675440B2
(en)
|
1992-06-18 |
1997-02-06 |
United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Recombinant (pseudomonas) exotoxin with increased activity
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
JP3053222B2
(ja)
|
1995-04-20 |
2000-06-19 |
ファイザー・インコーポレーテッド |
Ｍｍｐおよびｔｎｆ抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
|
ES2169355T3
(es)
|
1996-03-05 |
2002-07-01 |
Astrazeneca Ab |
Derivados de 4-anilinoquinazolina.
|
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
DE69716916T2
(de)
|
1996-07-13 |
2003-07-03 |
Glaxo Group Ltd., Greenford |
Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
|
|
CA2260898C
(en)
|
1996-07-18 |
2002-05-14 |
Pfizer Limited |
Phosphinate based inhibitors of matrix metalloproteases
|
|
PL331895A1
(en)
|
1996-08-23 |
1999-08-16 |
Pfizer |
Arylosulphonylamino derivatives of hydroxamic acid
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
DE69730151T2
(de)
|
1997-01-06 |
2005-08-04 |
Pfizer Inc. |
Cyclische sulfonderivate
|
|
AU721748B2
(en)
|
1997-02-03 |
2000-07-13 |
Pfizer Products Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
|
CA2279863A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
|
WO1998034918A1
(en)
|
1997-02-11 |
1998-08-13 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
CA2289102A1
(en)
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
JP2002501532A
(ja)
|
1997-05-30 |
2002-01-15 |
メルク エンド カンパニー インコーポレーテッド |
新規血管形成阻害薬
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
JP2001518470A
(ja)
|
1997-09-26 |
2001-10-16 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成阻害剤
|
|
WO1999024440A1
(en)
|
1997-11-11 |
1999-05-20 |
Pfizer Products Inc. |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
US6809184B1
(en)
|
1997-12-01 |
2004-10-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
US6296843B1
(en)
|
1998-04-03 |
2001-10-02 |
The Penn State Research Foundation |
Mutagenized IL 13-based chimeric molecules
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
IL139934A0
(en)
|
1998-05-29 |
2002-02-10 |
Sugen Inc |
Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same
|
|
CA2334958A1
(en)
*
|
1998-12-24 |
2000-07-06 |
New York Medical College |
Peptide mimics useful for treating disease
|
|
DE60039510D1
(de)
|
1999-05-27 |
2008-08-28 |
Us Gov Health & Human Serv |
Immunokonjugate mit hoher bindungsaffinität
|
|
US7091323B2
(en)
*
|
2001-04-24 |
2006-08-15 |
Bayer Corporation |
Human TIMP-1 antibodies
|
|
US20080095785A2
(en)
*
|
2001-11-30 |
2008-04-24 |
Soldano Ferrone |
Monoclonal antibodies to human high molecular weight-melanoma associated antigen
|
|
WO2006074071A1
(en)
|
2004-12-30 |
2006-07-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Framework residue substituted humanized col-1 antibodies and their use
|
|
US20060223096A1
(en)
|
2005-03-25 |
2006-10-05 |
Glycart Biotechnology Ag |
Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
|
|
EP2061800B1
(en)
|
2006-08-15 |
2015-07-29 |
The Trustees of the University of Pennsylvania |
Compositions comprising hmw-maa and fragments thereof, and methods of use thereof
|
|
US9697529B2
(en)
|
2012-03-13 |
2017-07-04 |
American Express Travel Related Services Company, Inc. |
Systems and methods for tailoring marketing
|
|
US10884952B2
(en)
|
2016-09-30 |
2021-01-05 |
Intel Corporation |
Enforcing memory operand types using protection keys
|